Apr
21
2020
On demand
Scaling up viral vector manufacturing with adherent and suspension cell cultures
Sponsor
Adherent and suspension bioreactors for viral vector manufacturing are evolving. However, for each choice, a robust manufacturing process is critical to ensure it is scalable for these novel therapies to reach the patients.
One of the first steps in designing a process is whether to use adherent or suspension cell cultures. Each modality has its advantages and disadvantages. In this webinar, the panelists will outline key considerations in choosing the right technology and some of the pitfalls that must be overcome to ensure success at large scale.
Participants learn:
- What factors to consider when choosing your cell culture
- The advantages and pitfalls with each type of culture
- The bioreactor choices available to support each type of culture
You might also like
High-throughput process & analytical platforms to accelerate gene therapy scale-up
P Starremans, K Warrington, N Jesuraj
25 April 2023
in 31
Days
Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells
Deepak Kumar
20 April 2023
in 26
Days
Analyzing full and empty AAV capsid ratio in less than 5 minutes
Åsa Hagner McWhirter
19 April 2023
in 25
Days
Development of anti-AAV assay for detection of pre-existing AAV immunity
Zhe Liu, John Chappell
18 April 2023
in 24
Days
Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution
Peter Yates
13 April 2023
in 19
Days